Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2012 - 2026)
Agios Pharmaceuticals (AGIO) reported Net Income towards Common Stockholders of -$99.2 million for Q1 2026, down 9.6% on a YoY basis from -$109.8 million in Q1 2025, and up 8.15% quarter-over-quarter from -$108.0 million in Q4 2025.
Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$99.2 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 9.6% year-over-year to -$99.2 million; the trailing twelve-month figure through Mar 2026 stood at -$423.2 million (down 163.82% YoY), and the FY2025 full-year result was -$412.8 million, down 161.27% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$99.2 million, up from -$108.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $947.9 million in Q3 2024, with the low at -$112.5 million in Q2 2025.
- Historically, Net Income towards Common Stockholders has averaged -$15.3 million across 4 years, with a median of -$95.9 million in 2023.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 1137.97% — and 2025, when it sank 110.91%.
- Agios Pharmaceuticals' Net Income towards Common Stockholders stood at -$95.9 million in 2023, then retreated by 0.61% to -$96.5 million in 2024, then dropped by 11.93% to -$108.0 million in 2025, then rose by 8.15% to -$99.2 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$99.2 million (Q1 2026), -$108.0 million (Q4 2025), and -$103.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | -99.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.23 Mn |
| Dec 31, 2025 | -108.04 Mn |
| Sep 30, 2025 | -103.43 Mn |
| Jun 30, 2025 | -112.54 Mn |
| Mar 31, 2025 | -90.54 Mn |
| Dec 31, 2024 | -96.52 Mn |
| Sep 30, 2024 | 947.92 Mn |
| Jun 30, 2024 | -97.70 Mn |
| Mar 31, 2024 | -83.18 Mn |
| Dec 31, 2023 | -95.94 Mn |
| Sep 30, 2023 | -91.32 Mn |
| Jun 30, 2023 | -85.45 Mn |
| Mar 31, 2023 | -82.52 Mn |
| Dec 31, 2021 | 3.96 Mn |
| Sep 30, 2021 | -4.51 Mn |
| Jun 30, 2021 | -3.43 Mn |
| Mar 31, 2021 | 1.97 Bn |
| Dec 31, 2020 | -13.12 Mn |
| Sep 30, 2020 | -19.80 Mn |
| Jun 30, 2020 | -8.98 Mn |